Porcine somatotropins with alterations in the alpha-helix 1 region, and combinations with other mutations

Abstract: The present invention relates to somatotropin analogues with amino acid changes in the alpha-helix 1 regions of said somatotropins, alone or in combination with mutations in the alpha-helix 3 and/or alpha-helix 2 regions, plus combinations with other changes to the native amino acid sequence of somatotropins. The resulting analogues are stable for formulation in sustained release formulations, while maintaining biological activity. Further, methods for conducting site-directed mutagenesis on DNA encoding proteins and/or polypeptide also are provided.

Description: BACKGROUND OF THE INVENTION The present invention relates to porcine somatotropin analogues with amino acid changes in the alpha-helix 1, alone or in combination with mutations with the alpha-helix 3 and/or alpha-helix 2 portion of said somatotropins and to methods for producing the changes in the alpha-helix 1, as well as other regions, of recombinantly-produced polypeptides or proteins. Administration of exogenous somatotropins significantly increases the growth performance of a variety of animals, in particular livestock animals such as swine, but also fish species, as well. This growth enhancement in livestock in particular is usually characterized by an increase in muscle mass accretion concomitant with a decrease in fat, resulting in larger, leaner animals. The feed efficiency of animals receiving exogenous somatotropin also is significantly improved, resulting from an increase in weight gain and a concomitant decrease in feed consumption. Exogenous administration of somatotropin is achieved in several ways, such as daily injections. In certain instances, however, other routes of administration may be preferred. For instance, an implanted device which allows sustained release of somatotropin over a defined time period may be helpful when treating certain livestock. A more desired route of administration is via an implanted device that allows sustained release over a defined period of time. Such a device would contain large amounts of porcine somatotropin in very high concentrations (ca 500 mg/ml). Further, a somatotropin molecule having high solubility and a low tendency to form insoluble, biologically inactive aggregates is required for such delivery uses. Somatotropins contain four α-helices which assemble to form an α-helical bundle (Abdel-Meguid et al, 1987). Its amino acid sequences derived from different species are disclosed in Abdel-Meguid et al, 1987). Typically, amino acid side chains projecting into the core of this structure are non-polar, hydrophobic and very tightly packed together in order to exclude penetration of a polar solvent (such as water or saline) into the center of the bundle. In the case of bovine somatotropin, which is related to porcine somatotropin in primary sequence, exposure of the hydrophobic face of α-helix 3 (from amino acid residues tyr 110 to leu 127 ) under protein concentrations in excess of 1 mg/ml promotes the formation of "associative intermediates", which are hypothesized to be a nucleating event in aggregate formation (Brems et al, 1986; Brems, 1988). These associative intermediates may represent alternate packing arrangements of this α-helix from several individual somatotropin molecules, resulting in a multimeric structure in which the hydrophobic faces of this helix are resequestered from the aqueous environment. Formation of the associative intermediates can be blocked by addition of an excess of a protein fragment-containing α-helix 3 (Brems, et al, 1986). In addition, extending the hydrophobic face of this helix, by replacing lysine at position 112 with leucine, greatly exacerbates the tendency to form associative intermediates (Brems, 1988). The present invention addresses the problem of low solubility of porcine somatotropin by altering the α-helix 3 regions of the somatotropin. Specifically, porcine somatotropins with enhanced solution stability in vitro are made by site-directed mutagenesis of α-helix 3. Both the hydrophobic and hydrophilic faces are targeted for mutagenesis. Recently site-directed mutations in the α-helix 3 region of bovine somatotropin resulted in suppressed growth of transgenic mice expressing the mutant somatotropin, a result suggesting that the α-helix 3 region is a region important for which biological activity may be maintained (Chen et al, 1990). In addition, α-helix 3 mutations are combined, where appropriate, with mutations in the helix 1 or helix 2 regions, and with double mutations in the DNA encoding cysteine at positions 183 and 191, where DNA encoding cysteine is replaced with either alanine or glutamic acid encoding DNA. The double mutations at positions 183 and 191 are described in EP355460, incorporated herein by reference thereto. Through the use of the mutations disclosed herein, somatotropins with enhanced solubility (stability), and thereby enhanced properties for sustained release, are provided. Porcine somatotropin is particularly useful in a sustained release form, and as such is a somatotropin of primary interest. A particularly useful example of the present mutation is mutation I122L, in which the isoleucine at position 122 in α-helix 3 is replaced with leucine. In combination with other mutations at positions 183 and 191 where the cysteines are replaced by alanine, a significant increase in the transition temperature of the protein's single tryptophan residue is obtained. The transition temperature is a measure of the thermal stability of the protein. In one of the most preferred mutations, enhanced solution stability is obtained when the I122L mutation is combined with mutations in which the cysteine-encoding DNA at positions 183 and 191 are altered to encode glutamic acid. In another preferred mutation, enhanced solution stability is achieved when the helix I double mutant A6TS11R is combined with mutations in which the cysteine-encoding DNA at positions 183 and 191 in the amino acid sequence are altered to encode glutamic acid. BRIEF DESCRIPTION OF THE DRAWINGS FIGURE 1: Restriction map of recombinant porcine somatotropin (rpST) DNA. The wide solid line represents the amino acid-encoding portion of rpST DNA; the slender line represents the 5' and 3' flanking, non-coding DNA sequence. Regions of rpST gene subject to site directed mutagenesis are numbered and indicated below the restriciton map, in which number 1 represents DNA encoding α-helix 1, number 2 represents DNA encoding α-helix 2, number 3 represents DNA encoding α-helix 3 and number 4 represents the DNA encoding the cysteines present at positions 183 and 191. The letters above the map denote the location of various restriction endonuclease restriction sites, in which RI=EcoRI, N=NdeI, B=BssHII, S=SacI, X=XbaI, Sm=SmaI and H=HindIII. FIGURE 2: Structure and restriction map of plasmid pEFF-902. This plasmid containes the pBR322 replication origin (Ori) and ampicillin resistance gene, the λP L promoter, the cII ribosome binding site and cI repressor gene from bacteriophage λ, the T 1 T 2 transcription terminator from the E. coli rrnB operon, a 60-base pair sequence from the deo regulatory region without promoters, and the rpST gene denoted as pGH. Relevant restriction sites are indicated. The rpST-containing DNA is excised from this plasmid by treatment with EcoRI and HindIII and cloned into mutagenesis vector pGEM3z(f+) as described in the text. FIGURE 3: Structure and partial restriction map of pGHGEM3Z. This phagemid contains the fl DNA replication origin, the pBR322 replication origin (Ori) and ampicillin resistance gene, the SP6 and T7 promoters, the lacZ gene cII ribosome binding site from bacteriophage λ and the rpST gene, denoted rpGH. Single stranded phagemid DNA is used as the template for site directed mutagenesis as described in the text. FIGURE 4: Bacterial expression plasmid pROpST is used for production of recombinant porcine somatotropins in bacteria ( E. coli ). The cII ribosome binding site is located between the EcoRI and NdeI restriction sites. The translational initiation codon for rpST is embedded in the NdeI site. Expression is driven by the λP L promoter. FIGURE 5: Structure of yeast expression plasmid YEp352-pST-I122L. This plasmid is a derivative of YEp352 and contains the rpST mutation, I122L, whose expression is driven by the inducible GAL1/GAL10 promoter from S . cerevisiae. The 3' untranslated DNA is derived from the yeast STE7 gene. The 2 µm element supports plasmid replication in yeast, and the URA3 provides a selectable marker for the transformant selection in yeast. This plasmid also carries the pBR322 origin of replication (not shown) and the ampicillin resistance gene. SUMMARY OF THE INVENTION The present invention relates to porcine somatotropin(s) with amino acid sequence changes in the α-helix 1 regions wherein said amino acid changes is a double mutation selected from the group consisting of A6TS11R or P8TS11R, either alone or in combination with mutations in the alpha-helix 3 and/or α-helix 2 regions of the somatotropin molecule. The resulting porcine somatotropin is more stable (soluble) than the native form of the somatotropin and maintains biological activity when formulated as a sustained release formulation of said somatotropin. In addition to the specific double mutation the porcine somatotropin may be further modified. For instance, modified (substituted or eliminated cysteines) or derivatized somatotropins in which one to four of the cysteine amino acid residues of said somatotropin are replaced by from one to four amino acid residues, separately selected from the amino acids, arginine, lysine, aspartic acid, glutamic acid, asparagine, glutamine, histidine, alanine, glycine, isoleucine, leucine, valine, phenylalanine, tryptophan, tyrosine, methionine, serine, threonine or proline; or in which all four cysteines are converted to cysteic acid. It is an object of the present invention, therefore, to provide novel porcine somatotropins which are more soluble than the native form of the molecule and are thus biologically effective when formulated, preferably in sustained release formulations. It is a further object of the present invention to provide site-directed mutagenesis techniques for making the somatotropins of the present invention. These and further objects of the invention will be apparent by the following detailed description of the invention. The plasmids, DNA sequences and microorganisms deposited in connection with the present patent application, except where specified to the contrary, are deposited in American Cyanamid Company's culture collection maintained in Princeton, New Jersey and are deposited pursuant to the Budapest Treaty with the American Type Culture Collection (ATCC) in Rockville, Maryland 20952, U.S.A. The DNA strains referred to hereinabove were deposited in the ATCC on August 23, 1988. They are pGEMpST-SX (ATCC number 40482), pRO211 (ATCC number 40483) and pEFF-902 (ATCC number 40484). It is recognized by those skilled in the art that these DNAs can be inserted into any appropriate expression system to obtain the somatotropins of the invention or mutations thereof. The E. coli K12 bacterial strains expressing some of the novel porcine somatotropins of the present invention also were deposited in the ATCC on September 21, 1990. These include pROpST-SXE-A6TS11R (ATCC 68412) and pROpST-SXE-A6TS11R + I122L (ATCC 68424). DETAILED DESCRIPTION OF THE INVENTION The porcine somatotropins of the present invention are provided by site directed mutagenesis, but other means such as chemically synthesizing the peptides and/or proteins may be employed in producing said somatotropins. Currently-utilized techniques for the alteration of the DNA sequence of a cloned segment of DNA at a specific defined site require the production of a single stranded form of that DNA. The single stranded DNA is annealed to a synthetic oligonucleotide which is complementary to a portion of that DNA except that the oligonucleotide contains within it a region of mismatch. The region of mismatch is usually located in the central portion of the oligonucleotide. In some instances, the oligonucleotide also contains a restriction endonuclease recognition site at or near the site of the mutation(s). The annealed mixture is then made double stranded and covalently closed by the addition of E. coli DNA polymerase I, large fragment and deoxynucleotide triphosphates in the presence of T4 DNA ligase and adenosine 5' triphosphate. The double stranded DNA is then transformed into an appropriate E. coli strain where the mismatched region of the DNA is repaired and replicated. Two populations of clones are obtained. Depending on which strand is chosen as the template for repair synthesis, a clone either contains the wild type or the altered (mutated) sequence. The clones which contain the mutated sequence, that which corresponds to the sequence of the oligonucleotide, are selected by hybridization to the radioactively-labelled oligonucleotide. Due to mismatch between the oligonucleotide and the wild type sequence, the radioactively-labelled oligonucleotide is more stably bound to the clones which contain the mutated sequence. Incubation at an appropriate temperature therefore discriminates between wild type and mutated clones. In cases in which the oligonucleotide also contains a restriction endonuclease cleavage site, digestion of candidate clones with the cognate restriction endonuclease reveals clones which contain the mutated sequence and provides another means of discriminating between wild type and mutated clones. The alterations in the identified clones then are confirmed by DNA sequencing of the relevant regions. Restriction fragments of plasmid clones containing the desired mutation(s) are reconstructed into expression plasmids suitable for expressing the mutant gene product in either bacteria or yeast, but not both. This reconstruction is achieved by standard subcloning procedures. In the following discussions, recombinant porcine somatotropin is described. The DNA and amino acid sequence of recombinant porcine somatotropin is provided hereinbelow. The most preferred recombinant porcine somatrotropin is a polypeptide sequence of 193 amino acids, in which the NH 2 -terminus has been modified to include 3 additional amino acids (met, asp, gln) and a deletion of the first amino acid (ala) found in some mature forms of pituitary-derived porcine somatotropin. However the 191 amino acids PST as well as other derivatives thereof, such as deletions at the NH 2 -terminus, additions thereof, and/or deletions and/or additions at the COOH-terminus are meant to form part of the present invention. Recombinant pST: NH 2 -met-asp-gln-phe-pro-ala-185 amino acids-ala-phe-COOH Pituitary pST: NH 2 -ala-phe-pro-ala-185 amino acids-ala-phe-COOH This modification results in a net increase of two additional amino acids in the recombinant pST protein and is described in EP355460. The numbering system employed in the description of the mutagenized derivatives of recombinant porcine somatotropin reflects this additional increase, and is easily applied by any practitioner skilled in the art. Recombinant Porcine Somatotropin Construction of pGEMpST-SX DNA Single stranded pGEMpST-SX DNA is the template DNA for all of the mutagenesis reactions and is prepared from pGHGEM3Z DNA by site directed mutagenesis. Cloning of the porcine somatotropin (rpST) gene into the phagemid pGEM-3z(f+), resulting in pGHGEM3Z, is achieved by the following general procedure. A fragment of DNA containing the pGHGEM3Z porcine somatotropin (rpST) gene is isolated from the bacterial expression plasmid pEFF-902 by cleavage with the restriction enzymes EcoRI and HindIII (Figure 1). The rpST gene-containing fragment is then purified by agarose gel electrophoresis. Double stranded phagemid DNA pGEM-3z(f+) is digested with EcoRI and HindIII, treated with calf intestinal EcoRI alkaline phosphatase and the large fragment purified by agarose gel electrophoresis. The two purified fragments are then mixed together and ligated with T4 DNA ligase. The mixture is transformed into bacteria and several resultant colonies grown. Plasmid DNA is prepared by a standard alkaline lysis method and the structure determined by digestion with appropriate restriction enzymes. A clone is isolated which contains the expected fragments and is designated pGHGEM3Z. nGEMpST-SX The aim of this mutagenesis is to create an rpST DNA sequence in which the DNA sequence encoding α-helix 2 is bounded on the 5' side (from positions 225-230 of the DNA coding region) by a SacI restriction site and the 3' side (from positions 285-290) by an XbaI restriction site. These alterations in the DNA sequence do not change the amino acid sequence of the rpST protein. The presence of these restriction endonuclease cleavage sites results in the creation of a "helix 2 cassette", so that mutations in the helix 2-encoding DNA can be conveniently and rapidly combined with appropriate mutations in the DNA encoding helix 3. The construction pf pGEMpST-SX is described below. The DNA sequences of synthetic oligonucleotides SacI293 and XbaI353 are described in Table 1. Single stranded pGHGEM3Z DNA is the substrate for mutagenesis and is prepared from purified phage by standard protocols. 2000 ng of this DNA is mixed with 100 ng each of the SacI293 and XbaI353 oligonucleotide, both of which have been phosphorylated at their 5' ends with adenosine 5' triphosphate and T4 polynucleotide kinase. The mixture is contained in a total volume of 10 µL in lX annealing buffer (lX annealing buffer is 75 mM KCl and 5 mM Tris-Cl, pH 8.0). The mixture is heated at 65 o C for 7 minutes followed by a 10 minute incubation at room temperature (RT). This procedure permits the oligonucleotides to anneal to the single stranded substrate (template) DNA. Annealed molecules are extended and converted to covalently closed, double stranded DNA by the addition of 22 µl H 2 O, 1 µl 20 mM ATP, 2 units each of T4 DNA ligase, and DNA polymerase I large fragment (for unit definition, see New England Biolabs catalogue, 1989), 2 µl 20X dNTP's (a mixture of the four deoxyribonucleotide 5' triphosphates each at a concentration of 2 mM) and 4 µl 10X "fill in" buffer (1X fill in buffer is 27.5 mM Tris-Cl, pH 7.5, 15 mM MgCl 2 , 2 mM DTT). After a one hour incubation at room temperature (RT), half of the reaction is introduced into HB101 competent cells by a standard protocol. Single colonies are apparent after overnight incubation at 37°C. Plasmid DNA is prepared by a standard procedure from 24 colonies, and digested, in separate reactions, with SacI and XbaI. Plasmid DNA's containing both restriction sites, which indicated the incorporation of both the SacI293 and XbaI353 oligonucleotides into the rpST gene, are further purified by introduction into HB101 competent cells as described previously. Plasmid DNA is prepared and digested in separate reactions with SacI and XbaI to verify the presence of each restriction site in the plasmid DNA, which is then confirmed by DNA sequence analysis of the relevant regions of the rpST DNA. Synthesis of Mutations in Helices 1, 2, or 3 Mutagenesis of the rpST gene in pGEMpST-SX is achieved as described below. The aim of the mutagenesis program is to generate an rpST molecule that has a decreased tendency to aggregate at high protein concentrations (>100 mg/ml). The focus is the hydrophobic face of helix 3, from amino acid residues 112 through 129, which is believed to be critical in the initiation of an aggregation reaction (Brems et al, 1986). Because the rpST gene employed here encodes an additional 2 amino acids at the amino-terminus, the total number of amino acid residues is 193, as opposed to the 191 residues found in pituitary-derived bovine and porcine somatotropin. Residues 112 through 129 correspond to residues 110 through 127 of bovine somatotropin (Abdel-Meguid et. al., 1987). Other regions of the molecule that are targeted for mutagenesis are helix 2, from residues 81 through 87, the hydrophilic face of helix 3 and helix 1 from residues 6 through 11. Combination mutants are generated by additional rounds of mutagenesis, or by subcloning relevant regions. The basic protocol used to obtain the L118E mutation and examples of all others are hereinafter described. Variations in the basic protocol are described in the appropriate examples. EXAMPLE 12 RECONSTRUCTION OF pST MUTATIONS INTO APPROPRIATE BACTERIAL EXPRESSION PLASMIDS The altered (mutation-bearing) clones are reconstructed into derivatives of the bacterial expression plasmid pRO211 (described in EPO173280 patent application incorporated herein by reference thereto), designated pROpST, pROpSTA34 and pROpSTE34. Plasmid pROpST contains pST DNA cloned into expression vector pRO211 and contains cysteine-encoding DNA at positions 183 and 191; pROpSTA34 contains alanine-encoding DNA and pROpSTE34 contains glutamic acid-encoding DNA at these positions. The pGEMpST altered clones are digested with EcoRI and SmaI and the small pST mutation-bearing fragment isolated. pROpSTA34 DNA is similarly treated, and the large, vector-containing DNA fragment is isolated. These purified fragments are ligated together with T4 DNA ligase and transformed into an appropriate bacterial strain, e.g.4300. This strain contains a temperature sensitive λ repressor, so that expression from the λP L promoter is prevented at 30°C, but permitted at 42°C, at which temperature the repressor is inactivated. Introduction of altered pGEMpST DNA fragments into pROpSTE34 DNA is achieved precisely as described for pROpSTA34. Introduction of altered pGEMpST DNA fragments into pROpST is identical to that described for pROpSTA34, except that both pGEMpST and pROpSTA34 plasmids are digested with EcoRI and HindIII. Table II lists the bacterial expression plasmids into which the mutated pST genes are introduced. pST mutation A6T, is introduced into a derivative of pROpSTE34 as described for pROpSTE34. This derivative, pROpSTE34T 1 T 2 , contains a ca. 1 kb HindIII fragment at the 3' end of the pST coding DNA, which contains the transcription terminator T 1 T 2 from the E. coli rrnB operon (the ribosomal RNA B operon). EXPRESSION VECTOR CONSTRUCTIONS: AMINO ACID CONSTITUTION AT POSITIONS 183 AND 191 Amino acid encoded at 183 and 191 Mutation cysteine alanine glutamic acid I122L + + + A6TS11R + A6TS11R+I122L + P8TS11R+I122L + P8TS11R + EXAMPLE 13 CONSTRUCTION OF HELIX 1 COMBINATION MUTANTS A6TS11R+E34 AND P8TS11R+E34 Double mutation A6TS11R, in which the alanine at position 6 is replaced with threonine and serine at position 11 is replaced with arginine, is combined with the E34 mutations (described in EP355460), in which the DNA encoding cysteine at positions 183 and 191 are replaced with glutamic acid. The resultant rpST gene therefore contains mutations in both the NH 2 - (A6TSllR) and COOH-encoding regions (E34) of the rpST DNA. The resulting plasmid is designated pROpSTE-A6TSllR. The altered, small, rpST-containing EcoRI/SmaI fragment from pML/pGH14, which contains the A6TSllR mutations, is joined to the large EcoRI/SmaI fragment from plasmid pROpSTE-T 1 T 2 . This latter plasmid is the pST expression plasmid, which also contains the strong transcription terminator from the E. coli rrnB operon (T 1 T 2 ) at the 3' end of the rpST-encoding DNA. Another double mutation, P8TS11R, in which the proline-encoding DNA at position 8 is mutated to encode threonine, and the serine-encoding DNA is mutated to encode arginine is combined with the E34 mutations (described in EP355460), in which the DNA encoding cysteine at positions 183 and 191 are replaced with glutamic acid. The resultant rpST gene therefore contains mutations in both the NH 2 - (P8TS11R) and COOH-encoding regions (E34) of the rpST DNA. The resulting plasmid is designated pROpSTE-P8TS11R. The same strategy is employed in the construction of pROpSTE-P8TS11R as in pROpSTE-A6TS11R, except that plasmid pML/pGH18, which contains the P8TS11R double mutation is used as the source of the altered rpST DNA. A6TS11R&I122L+E34 and P8TS11R+I112L+E34 The I112L helix 3 mutation described above is combined with each of the two helix 1 mutations, A6TS11R and P8TS11R and the E34 mutations. The resulting plasmids are designated pROpST-SXE-A6TS11R+I122L and pML/pGH18-SXE-I122L, respectively. pROpST-SXE-A6TS11R+I122L is constructed by joining the small I122L-containing BssHII/HindIII fragment with the large BssHII/HindIII fragment purified from pROpSTE-A6TS11R. This resulting plasmid contains the helix 2 cassette, defined by the SacI and XbaI restriction sites that flank the 5' and 3' ends of helix 2-encoding DNA previously described but does not contain the T 1 T 2 transcription terminator. Plasmid pML/pGH18-SXE-I122L is constructed in an identical fashion except that plasmid pML/pGH18 is used as the source of the large fragment, carrying the P8TS11R double mutations. This altered plasmid does not contain the T 1 T 2 transcription terminator, and does carry the helix 2 cassette. EXAMPLE 14 STABILITY PROFILES OF MODIFIED RECOMBINANT SOMATOTROPINS The procedure described to determine stability profiles is as follows. The concentrated solution of the recombinant (animal) somatotropin derivative (up to 100mg/ml) in phosphate buffered saline pH7.4 (NaH 2 PO 4 H 2 O3.45gm, Na 2 HPO 4 3.55 gm, NaCl 9.50 gm dissolved in distrilled water 1000 ml) is prepared. This is filtered through a millipore sterile Millex-0.22µm filter unit and 0.1 ml aliquots placed into tubes. These are placed in a 43°C oven and removed at the required intervals. The contents are then diluted with phosphate buffered saline. The supernatant is assayed for monomer and dimer content by HPLC. A mass balance is done. Any precipitated material is recorded. Results are compared with the initial concentrations and a stability profile documented. Alternately, a somatotropin derivative exhibiting poor solubility at pH7.4 is dissolved at a less preferred pH (4-10) or is evaluated as a suspension. The results of solution stability studies for the altered rpST proteins are summarized in Table III. rpST MUTANT PROTEIN SOLUBILITY IN VITRO Mutation % Soluble Days Incubated at 43°C A34 32 14 I122L+A34 44 14 E34 70.0(3) 14 67 17 I122L+E34 62.0(2) 14 66.3(3) 17 A6TS11R+E34 68.5(2) 14 P8TS11R+E34 62 14 A6TS11R+I122L+E34 36 14 P8TS11R+I122L+E34 2 14 Percent solubility is expressed as the fraction of the total remaining in solution x 100. (See Example 14). Where more than one determination is made, an average % solubility is presented, and the number of independent determinations is given in parentheses. The rpST mutants are present in either the A34 or E34 backgrounds. A34 rpST contains alanine, instead of cysteine, at positions 183 and 191. E34 rpST contains glutamate instead of cysteine at positions 183 and 191. EXAMPLE 15 HYPOX RAT TEST METHOD FOR DETERMINING THE GROWTH ENHANCEMENT OF ANIMALS RECEIVING RECOMBINANT (ANIMAL) SOMATOTROPIN DERIVATIVE The efficacy of the recombinant animal somatotropin derivatives of the present invention for altering the growth rate of animals is determined utilizing the hypophysectomized (hypox) rat assay. The hypophysectomized rat does not produce its own somatotropin and is sensitive to injected somatotropin. The response measured is growth over a period of time such as 10 days and is presented in Table IV as percent of the biological activity of the rpST positive control, which is included in every trial. BIOLOGICAL DATA (HYPOX RAT, RRA) AND THERMAL STABILITY FOR rpST MUTANT PROTEINS Mutation(s) Hypox rat RRA T (m) (°C) A34 112.8 173.5 nd I122L+A34 97.4 225.8 79 E34 90.52(5) 51.4(7) 62.0(6) I122L+E34 66.66(5) 80.28(5) 62.67(5) A6TS11R+E34 80.7(4) 135.0(4) 64.0(4) P8TS11R+E34 129.7 78.5 65 A6TS11R+I122L+E34 116.7 112.8 61 P8TS11R+I1221+E34 127.9 89.3 64 EXAMPLE 16 LIVER RADIO-RECEPTOR ASSAY FOR DETERMINING ABILITY OF ALTERED RECOMBINANT SOMATOTROPIN TO BIND TO SOMATOTROPIN RECEPTOR IN VITRO An in vitro radioreceptor assay is employed to assess the ability of the recombinant somatotropins of the present invention to compete with 125 I-rpST for binding to somatotropin receptor from purified liver membranes. The results of these assays are given as percent rpST binding and are presented in Table IV. EXAMPLE 17 NITROGEN BALANCE EXPERIMENTS CONDUCTED WITH rpST MUTANT I122L+E34 To evaluate biological activity of altered rpST proteins carrying the I122L mutation in vivo , a nitrogen balance study is conducted as described in EP355460. Subcutaneous administration of pST to growing pigs increases the quantity of protein deposited in the body, primarily as muscle. The use of a nitrogen balance test provides a measure of the change in amount of protein deposited by an animal. Since protein contains a fixed amount of nitrogen, analyzing feedstuffs and excreta for nitrogen provide an accurate estimate of the status of protein deposition. Thus, nitrogen balance is a measure of the amount of nitrogen consumed in the feed and the amount excreted in the urine and feces with the amount retained (deposited) calculated by difference. Nitrogen retention is most accurately estimated as the amount of nitrogen retained as a percentage of the amount of nitrogen digested (nitrogen consumed minus fecal nitrogen). In this study, the cysteine residues at positions 183 and 191 or the rpST I122L variant have been replaced with glutamic acid. The results of this analysis demonstrate full biological activity of the altered rpST molecule relative to the rpST control. EXAMPLE 18 DETERMINATION OF THERMAL STABILITY USING FLUORESCENCE SPECTROSCOPY The thermal stability of altered rpST is inferred from measuring the intrinsic tryptophan fluorescence as a function of temperature. The rpST molecule contains a single tryptophan residue, whose intrinsic fluorescence is severely quenched in the "native state". Increasing temperature, or decreasing pH, causes a characteristic increase in fluorescence, which is presumably due to a loss of structure at least in the immediate vicinity of the otherwise buried tryptophan residue. A "melting profile" of fluorescence versus increasing temperature reveals a sigmoidal curve, in which fluorescence remains quenched up until a temperature that is characteristic for a given rpST derivative. A sharp increase in fluorescence over a rather narrow temperature range then ensues. The temperature that defines the midpoint of this increase in fluorescence is designated T (m) and is a reflection of the protein's thermal stability. The T (m) of the rpST of the present invention is determined by the method of Burger, et al 1966, except that 295 nm is used as the excitation wavelength and the emission fluorescence is read using a 355 nm cut off filter. The T (m) of the rpST of the present invention is summarized in Table IV. These data reveal a marked increase in T(m) of 79°C for I122L. EXAMPLE 19 GENERATION OF THE I122L MUTATION BY THE POLYMERASE CHAIN REACTION METHOD The I122L mutation is introduced into the rpST gene by site-directed mutagenesis utilizing an application of polymerase chain reaction technology as described by Sarkar and Sommer 1990, incorporated herein by reference. The three oligonucleotide primers used are listed in Table I and include oligonucleotides SacI293, L120-3 and PvuII634. The rpST gene-containing EcoRI/HindIII fragment from plasmid pGEMpST-SX is used as the template. Fifteen cycles of polymerase chain reaction (hereafter referred to as PCR) is performed on 1 ng template rpST DNA with 1 µM each of the L120-3 and PvuII634 oligonucleotide primers, dNTP's and Tag DNA polymerase, as specified by the manufacturer. This reaction results in a 227 bp DNA fragment, which contains the I122L mutation. This fragment is purified by agarose gel electrophoresis and is used as a PCR primer in combination with oligonucleotide primer SacI293 and the rpST-containing EcoRI/HindIII template fragment in 15 additional cycles of PCR. The resultant 361 bp fragment is cleaved with restriction endonucleases SacI and PvuII, purified by agarose gel electrophoresis and ligated into the large gel-purified, SacI/PvuII pGEMpST-SX DNA fragment. The ligation mixture is transformed into HB101 competent cells. Plasmid DNA of the resulting transformants is screened for the presence of the I122L mutation precisely as described for L118E, except that oligonucleotide L120-3 is used as the radio-labelled hybridization probe and only one round of screening is performed. The presence of the I122L mutation and the absence of additional mutations introduced by the PCR reactions is confirmed by DNA sequence analysis. The plasmid bearing this mutation is designated pGEMpST-SX-I122L PCR . EXAMPLE 20 RECONSTRUCTION OF rpST MUTATION I122L INTO A PLASMID SUITABLE FOR EXPRESSION IN YEAST In order to express the I122L mutation-bearing rpST gene in the yeast, Saccharomyces cerevisiae , the rpST encoding DNA must be operably linked to a promoter sequence derived from this yeast. The ends of the small rpST-bearing NdeI/HindIII fragment from pROpST-SXE-I122L are made flush by treatment of this DNA with the large Klenow fragment of DNA polymerase I after the plasmid is cleaved with NdeI and HindIII. This fragment is purified by gel electrophoresis and joined with the large SalI/SphI fragment of plasmid is YEp352-2. The ends of this latter fragment are made flush by treatment with S1 nuclease. This plasmid is a YEp352-derivative, which has been modified to additionally contain the divergent GAL1/GAL10 promoter (Johnston and Davis, 1984), and the 3' untranslated region derived from the STE7 gene (Teague, et al, 1986). The resulting plasmid is designated YEp352-pST-I122L (Figure 5). Expression of this rpST variant in yeast is accomplished by culturing yeast cells transformed with this plasmid in a synthetic complete medium (Sherman, Fink and Hicks, 1986) that lacks uracil and contains 2% galactose as the sole carbon source at 30°C for several hours, or however necessary to achieve maximal rpST gene induction and rpST production. Although any yeast strain carrying a mutation in the URA3 gene can be used as the host, it is preferable to employ a yeast strain that is deficient in protease production and is GAL+, such as BJ5457 (genotype MATα pep4::HIS3 prbl-Δ trpl ura3-52 leu2-Δ his3-Δ lys2-801 can1 GAL+). This strain is deposited with the Yeast Genetic Stock Center, University of California, BJ5457. BIBLOGRAPHY 1. Abdel-Meguid et al. (1987), Proc. Natl. Acad. Sci. USA 84 , 6434-6437. 2. Brems (1988), Biochemistry 27 , 4541-4546. 3. Brems et al. (1986), Biochemistry 25 , 6539-6543. 4. Brems et al (1988), Proc. Natl. Acad. Sci. USA 84 , 3367-3371. 5. Burger, H.G., Edelhoch, H. and Condliffe, P.G., (1966) Endocrinology 78 , 98-102 . 6. Chen, W.Y. et al. (1990), Proc. Natl. Acad. Sci USA 87 , 5061-5065 . 7. Johnston and Davis (1984) Molecular and Cellular Biology 4 , 1440-1448 . 8. Sarkar and Sommer (1990), Biotechniques 8 , 404-407 . 9. Teague et al (1986), Proc. Nat. Acad. Sci USA 83 , 7371-7375. 10. Sherman, F. Fink, G. R. and Hicks, J.B. (1986), "Laboratory Course Material for Methods in Yeast Genetics" Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 163-168. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Meir Fischer, Michael Richard Lebens, Deborah Tardy Chaleff (ii) TITLE OF INVENTION: Somatotropins with Alterations in the Alpha-Helix 1 Region, and Combinations with Other Mutations (iii) NUMBER OF SEQUENCES: 1 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: John P. White, Cooper & Dunham (B) STREET: 30 Rockefeller Plaza (C) CITY: New York (D) STATE: New York (E) COUNTRY: United States of America (F) ZIP: 10112 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: 3.5" Double Sided Hard Disk (B) COMPUTER: IBM PC AT (C) OPERATING SYSTEM: MS-DOS (D) SOFTWARE: ASCII converted from IBM Displaywrite 4 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: White, John P. (B) REGISTRATION NUMBER: 28,678 (C) REFERENCE/DOCKET NUMBER: 38360/JPW/LSW (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 212 977 9550 (B) TELEFAX: 212 664 0525 (C) TELEX: (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 193 base pair (B) TYPE: nucleic acid (C) STRANDEDNESSS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: (iii) HYPOTHETICAL: (iv) ANTI-SENSE: (v) FRAGMENT TYPE: (vi) ORIGINAL SOURCE: (A) ORGANISM: (B) STRAIN: (C) INDIVIDUAL ISOLATE: (D) DEVELOPMENTAL STAGE: (E) HAPLOTYPE: (F) TISSUE TYPE: (G) CELL TYPE: (H) CELL LINE: (I) ORGANELLE: (vii) IMMEDIATE SOURCE: (A) LIBRARY: (B) CLONE: (viii) POSITION IN GENOME: (A) CHROMOSOME/SEGMENT: (B) MAP POSITION: (C) UNITS: (ix) FEATURE: (A) NAME/KEY: (B) LOCATION: (C) IDENTIFICATION METHOD: (D) OTHER INFORMATION: (x) PUBLICATION INFORMATION: (A) AUTHORS: (B) TITLE: (C) JOURNAL: (D) VOLUME: (E) ISSUE: (F) PAGES: (G) DATE: (H) DOCUMENT NUMBER: (I) FILING DATE: (J) PUBLICATION DATE: (K) RELEVANT RESIDUES: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Claims: Claims for the following Contracting States : AT, BE, CH, LI, DE, DK, FR, GB, IT, LU, NL, SE A porcine somatotropin comprising: a double mutation of said somatotropin in the alpha-helix 1 region thereby making said somatotropin more soluble than the native form of said somatotropin while maintaining biological activity in a sustained release formulation and wherein said alpha-helix 1 double mutation is selected from the group consisting of A6TS11R or P8TS11R. A porcine somatotropin comprising; a mutation of said somatotropin in the alpha-helix 3 region and a double mutation in the alpha-helix 1 region thereby making said somatotropin more soluble than the native form of said somatotropin while maintaining biological activity in a sustained release formulation and wherein said alpha-helix 3 mutation is I122L and wherein said alpha-helix 1 double mutation is A6TS11R. The somatotropin according to Claim 1, wherein of the four (4) cysteine, two in the small loop and two in the large loop, at least one (1) is replaced by amino acids individually selected from the group consisting of arginine, lysine, aspartic acid, glutamic acid, asparagine, glutamine, bistidine, alanine, glycine, isoleucine, leucine, valine, phenylalanine, tryptophan, tyrosine, methionine, serine, threonine and proline. The somatotropin according to Claim 3, wherein said amino acids are individually selected from the group consisting of glutamic acid and alanine. The somatotropin according to Claim 4, wherein the cysteines at positions 183 and 191 are replaced with glutamic acid. The somatotropin according to Claim 2, wherein of the four (4) cysteines two In the small loop and two in the large loop, at least one (1) is replaced by amino acids individually selected from the group consisting of arginine, lysine, aspartic acid, glutamic acid, asparagine, glutamine, histidine, alanine, glycine, isoleucine, leucine, valine, phenylalanine, tryptophan, tyrosine, methionine, serine, threonine and proline. The somatotropin according to Claim 6, wherein said amino acids are individually selected from the group consisting of glutamic acid and alanine. The somatotropin according to Claim 7, wherein the cysteines at positions 183 and 191 are replaced with glutamic acid. The somatotropin according to Claim 1 wherein the somatotropin is met-asp-gln-des(ala) porcine somatotropin. The somatotropin according to Claim 2 wherein the somatotropin is met-asp-gln-des(ala) porcine somatotropin. Claims for the following Contracting States : ES, GR Use of a porcine somatotropin comprising: a double mutation of said somatotropin in the alpha-helix 1 region thereby making said somatotropin more soluble than the native form of said somatotropin while maintaining biological activity in a sustained release formulation and wherein said alpha-helix 1 double mutation is selected from the group consisting of A6TS11R or P8TS11R, for increasing the growth performance of animals. Use of a porcine somatotropin comprising: a mutation of said somatotropin in the alpha-helix 3 region and a double mutation in the alpha-helix 1 region thereby making said somatotropin more soluble than the native form of said somatotropin while maintaining biological activity in a sustained release formulation and wherein said alpha-helix 3 mutation is I122L and wherein said alpha-helix 1 double mutation is A6TS11R, for increasing the growth performance of animals. The use according to Claim 1, wherein of the four (4) cysteine, two,in the small loop and two in the large loop, at least one (1) is replaced by amino acids individually selected from the group consisting of arginine, lysine, aspartic acid, glutamic acid, asparagine, glutamine, histidine, alanine, glycine, isoleucine, leuctine, valine, phenylalanine, tryptophan, tyrosine, methionine, serine, threonine and proline. The use according to Claim 3, wherein said amino acids are individually selected from the group consisting of glutamic acid and alanine. The use according to Claim 4, wherein the cysteines at positions 183 and 191 are replaced with glutamic acid. The use according to Claim 2, wherein of the four (4) cysteines two in the small loop and two in the large loop, at least one (1) is replaced by amino acids individually selected from the group consisting of arginine, lysine, aspartic acid, glutamic acid, asparagine, glutamine, histidine, alanine, glycine, isoleucine, leucine, valine, phenylalanine, tryptophan, tyrosine, methionine, serine, threonine and proline. The use according to Claim 6, wherein said amino acids are individually selected from the group consisting of glutamic acid and alanine. The use according to Claim 7, wherein the cysteines at positions 183 and 191 are replaced with glutamic acid. The use according to Claim 1, wherein the somatotropin is met-asp-gln-des(ala) porcine somatotropin. The use according to Claim 2, wherein he somatotropin is met-asp-gln-des(ala) porcine somatotropin.

Inventors: CHALEFF DEBORAH TARDY, FISCHER MEIR, LEBENS MICHAEL RICHARD, CHALEFF, DEBORAH TARDY, FISCHER, MEIR, LEBENS, MICHAEL RICHARD
Applicants: AMERICAN CYANAMID CO, BIO TECHNOLOGY GENERAL CORP, AMERICAN CYANAMID COMPANY, BIO-TECHNOLOGY GENERAL CORPORATION
Application year: 1991
Main classification: C12N15
IPC codes: C07K14, C12N15, A61P43, A61K38, C07K1